G-CSF to reduce side effects during glioblastoma treatment
Treatments studied
Part of Cancer clinical trials.
This trial is testing whether a drug called G-CSF (which helps boost white blood cells) can help people with glioblastoma who are already receiving standard treatment with radiation and chemotherapy (temozolomide). It aims to see if G-CSF can reduce side effects and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been recently diagnosed with a type of brain tumor called glioblastoma (GBM).
- Your tumor must have a specific genetic marker called MGMT methylation.
- You must be planning to receive the standard treatment: radiation therapy plus the chemotherapy drug temozolomide.
- You must be 18 years old or older and have a good performance status (able to care for yourself).
- You must be able to have repeated brain MRI scans with contrast dye.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a more focused, stronger dose of radiation can improve outcomes for people 65 and older with newly diagnosed glioblastoma. It compares this approach to standard radiation to see if it's safe and effective.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial tests a new two-part treatment (DB107-RRV and DB107-FC) combined with radiation, with or without the chemotherapy drug temozolomide, for people with newly diagnosed high-grade glioma. It aims to see if this approach is safe and effective.
This trial tests a special radiation boost that targets low-oxygen areas of the brain tumor during standard radiation therapy. It may help control the tumor better for people with newly diagnosed or recurrent glioblastoma.
This trial tests whether adding the drug ruxolitinib to standard radiation and chemotherapy (temozolomide) helps people with a newly diagnosed brain tumor called glioblastoma. It aims to see if the combination keeps the tumor from growing longer than the standard treatment alone.
This trial tests whether using your own blood stem cells to support high-dose chemotherapy can help treat newly diagnosed glioblastoma, an aggressive brain cancer. It aims to improve outcomes for patients whose tumors have a specific genetic marker (unmethylated MGMT) and who have had surgery.
Hear when a new MGMT-Methylated Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.